Our Science – UOB Website
Urologic Oncology Branch
The Urologic Oncology Branch conducts clinical and basic research designed to develop better methods for detection, prevention, and therapy of patients with kidney cancer, prostate cancer and bladder cancer.
In the Urologic Oncology Branch, patients with non-inherited as well as inherited forms of kidney cancer, including von Hippel-Lindau (VHL) disease, hereditary papillary renal carcinoma (HPRC), Birt-Hogg-Dube (BHD) syndrome, hereditary leiomyomatosis renal cell carcinoma (HLRCC) and succinate dehydrogenase deficient kidney cancer are evaluated and managed. In the laboratory, studies are under way to determine the molecular mechanisms of the kidney cancer disease genes, including the VHL, MET, FLCN (BHD), fumarate hydratase and succinate dehydrogenase genes, in order to develop novel approaches to therapy. Clinical trials are being conducted to evaluate new therapies for patients
with localized as well as advanced kidney cancer.
The Urologic Oncology Branch has a growing program in prostate cancer. Patients with known or suspected localized and locally advanced prostate cancer undergo advanced MRI imaging followed by fusion image guided biopsy to diagnosis and characterize the cancer. Patients may then be managed with robotic surgery or be followed with active surveillance and intermittent imaging. Metabolic imaging is being performed to help characterize the localized prostate cancer and genomic analysis is being performed on tumor samples to provide the basis for the development of effective forms of therapy for this disease.
The Urologic Oncology Branch also has a growing program in genomics and targeted therapy for bladder cancer, including therapy targeting EGFR, FGFR3 and other mutated bladder cancer genes. Clinical trials for patients with bladder cancer are currently underway.
This page was last updated on 7/1/2014.